Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Levi, Charlène; Frémeaux-Bacchi, Véronique; Zuber, Julien; Rabant, Marion; Devriese, Magali; Snanoudj, Renaud; Scemla, Anne; Amrouche, Lucile; Mejean, Arnaud; Legendre, Christophe; Sberro-Soussan, Rebecca. Transplantation. 2017; 101: p.2924-2930. doi:10.1097/TP.0000000000001909Article
Épidémiologie clinique